LenioBio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 45

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.57M

  • Investors
  • 11

LenioBio General Information

Description

Developer of a synthetic biology and protein expression technology designed to accelerate and simplify protein expression for complex and novel proteins. The company offers a cell-free eukaryotic expression system compatible with linear deoxyribonucleic acid (DNA) and artificial intelligence-designed proteins, enabling biotech and pharmaceutical researchers to access post-translationally modified proteins without relying on cloning or cell lines.

Contact Information

Formerly Known As
Lenio Biotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Erkrather Straße 401
  • 40231 Dusseldorf
  • Germany
+49 0211
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Erkrather Straße 401
  • 40231 Dusseldorf
  • Germany
+49 0211

LenioBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LenioBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Grant 01-Jun-2026 $2.57M Completed Generating Revenue
11. Later Stage VC 15-Jul-2025 Completed Generating Revenue
10. Grant 01-Jul-2025 Completed Generating Revenue
9. Later Stage VC (Series B) 13-May-2024 Completed Generating Revenue
8. Later Stage VC 31-Jul-2023 Completed Generating Revenue
7. Grant 01-Feb-2023 Completed Generating Revenue
6. Grant 01-Apr-2022 Completed Generating Revenue
5. Later Stage VC (Series A) 18-Feb-2022 Completed Generating Revenue
4. Accelerator/Incubator 09-Oct-2020 $4.48M Completed Generating Revenue
3. Grant 23-Aug-2019 $2.64M $4.48M Completed Generating Revenue
To view LenioBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

LenioBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a synthetic biology and protein expression technology designed to accelerate and simplify protein expressio
Drug Discovery
Dusseldorf, Germany
45 As of 2026

Ipswich, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LenioBio Competitors (3)

One of LenioBio’s 3 competitors is New England Biolabs, a Corporation company based in Ipswich, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
New England Biolabs Corporation Ipswich, MA
Sutro Biopharma Formerly VC-backed South San Francisco, CA
Ginkgo Bioworks Formerly VC-backed Boston, MA
You’re viewing 3 of 3 competitors. Get the full list »

LenioBio Patents

LenioBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025176699-A1 A system and method for cell-free unnatural amino acid incorporation Pending 20-Feb-2024
EP-4527938-A1 Method for cell-free polypeptide synthesis Inactive 22-Sep-2023
EP-4780977-A1 Method for cell-free polypeptide synthesis Pending 22-Sep-2023
WO-2025061737-A1 Method for cell-free polypeptide synthesis Inactive 22-Sep-2023
DE-102023115905-A1 Controllable disruption of eukaryotic protoplasts to release intact cell organelles Pending 20-Jun-2022 C12M45/02
To view LenioBio’s complete patent history, request access »

LenioBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LenioBio Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Defence Agency Government
Coalition for Epidemic Preparedness Innovations Impact Investing
European Health and Digital Executive Agency (HaDEA) Corporation
German Aerospace Center Corporation
Bundesministerium für Bildung und Forschung Government
You’re viewing 5 of 11 investors. Get the full list »

LenioBio FAQs

  • When was LenioBio founded?

    LenioBio was founded in 2016.

  • Where is LenioBio headquartered?

    LenioBio is headquartered in Dusseldorf, Germany.

  • What is the size of LenioBio?

    LenioBio has 45 total employees.

  • What industry is LenioBio in?

    LenioBio’s primary industry is Drug Discovery.

  • Is LenioBio a private or public company?

    LenioBio is a Private company.

  • What is LenioBio’s current revenue?

    The current revenue for LenioBio is .

  • How much funding has LenioBio raised over time?

    LenioBio has raised $51.9M.

  • Who are LenioBio’s investors?

    European Defence Agency, Coalition for Epidemic Preparedness Innovations, European Health and Digital Executive Agency (HaDEA), German Aerospace Center, and Bundesministerium für Bildung und Forschung are 5 of 11 investors who have invested in LenioBio.

  • Who are LenioBio’s competitors?

    New England Biolabs, Sutro Biopharma, and Ginkgo Bioworks are competitors of LenioBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process